→ Metabolic and endocrine disorder-focused Lipocine $LPCN on Wednesday said it was suing Clarus Therapeutics for its recently approved oral testosterone replacement therapy, Jatenzo, alleging the latter has infringed on 6 its US patents. Clarus shot back, saying “When the facts are brought before the court, we are confident that Lipocine’s assertions will be found to be without merit.”
→ Riding the wave of its promising — but early stage — snapshot of its Pfizer $PFE-partnered hemophilia A gene therapy, Sangamo Therapeutics $SGMO on Wednesday said it was offering up more shares to raise funds in a public offering — the size of the offering and price per share will be revealed later.
→ DBV Technologies — which has fallen behind arch rival Aimmune Therapeutics $AIMT — in the race to get a peanut allergy treatment on the US market, also announced plans for an offering, reserved for specific categories of investors, on Wednesday. The company $DBVT is offering about 5.2 million shares in the United States, Canada and certain other countries outside of Europe, in addition to a private placement of ordinary shares in Europe.
→ Aveo Pharmaceuticals $AVEO — whose long suffering cancer drug tivozanib could be withdrawn from the EU market this summer, unless mature overall survival data from a key trial supports its use — has priced its offering of 21.7 million shares, as well as the accompanying short-term warrants. Each share and accompanying warrant is priced at $1.15, and the company expects to raise proceeds of roughly $25 million.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription